Outlook Therapeutics (OTLK) Interest Coverage Ratio (2015 - 2023)
Outlook Therapeutics (OTLK) reported Interest Coverage Ratio of 60480.67 for Q3 2023, down 1.02% quarter-over-quarter from 59872.62 in Q2 2023.
Outlook Therapeutics (OTLK) Interest Coverage Ratio (2015 - 2023) Analysis & Trends
Outlook Therapeutics (OTLK) has 8 years of Interest Coverage Ratio data on file, last reported at 60480.67 in Q3 2023.
- Interest Coverage Ratio for Q3 2023 came in at 60480.67, changed N/A year-over-year; the trailing twelve-month figure through Jun 2024 was 297499.04 (down 64.93% YoY), and the FY2024 annual result was 22.71, down 8.22% from the prior year.
- Interest Coverage Ratio eased to 60480.67 in Q3 2023 per OTLK's latest filing, from 59872.62 in the prior quarter.
- Over five years, Interest Coverage Ratio peaked at 5.22 in Q2 2019 and troughed at 60480.67 in Q3 2023.
- A 4-year average of 11012.9 and a median of 50.42 in 2021 frame the typical range for Interest Coverage Ratio.
- The sharpest annual moves came in 2019 and 2020: Interest Coverage Ratio increased 17.08% in 2019, then tumbled 771.37% in 2020.
- A 4-year view of Interest Coverage Ratio shows it stood at 13.69 in 2019, then plunged by 549.08% to 88.88 in 2020, then soared by 43.27% to 50.42 in 2021, then tumbled by 119856.95% to 60480.67 in 2023.
- Business Quant data shows OTLK's Interest Coverage Ratio at 60480.67 in Q3 2023, 59872.62 in Q2 2023, and 50.42 in Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | 3.58 |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -258.33 |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | 11.50 |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | 11.79 |
| 10 | Outlook Therapeutics | 51.56 Mn | 43.81 Mn | -21,888.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | -60,480.67 |
| Jun 30, 2023 | -59,872.62 |
| Mar 31, 2021 | -50.42 |
| Dec 31, 2020 | -88.88 |
| Sep 30, 2020 | -526.18 |
| Jun 30, 2020 | -26.78 |
| Mar 31, 2020 | -9.72 |
| Dec 31, 2019 | -13.69 |
| Sep 30, 2019 | -60.39 |
| Jun 30, 2019 | -5.22 |
| Mar 31, 2019 | -7.31 |
| Dec 31, 2018 | -9.15 |
| Sep 30, 2018 | 15.74 |
| Jun 30, 2018 | -6.29 |
| Mar 31, 2018 | -7.42 |
| Dec 31, 2017 | -4.43 |
| Sep 30, 2017 | -1.36 |
| Jun 30, 2017 | -4.20 |
| Mar 31, 2017 | -6.30 |
| Dec 31, 2016 | -36.38 |